S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

Catalent Stock Price, Forecast & Analysis (NYSE:CTLT)

$52.04
+0.49 (+0.95 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$51.41
Now: $52.04
$52.38
50-Day Range
$46.91
MA: $49.27
$51.54
52-Week Range
$29.23
Now: $52.04
$58.38
Volume573,053 shs
Average Volume793,164 shs
Market Capitalization$7.61 billion
P/E Ratio32.12
Dividend YieldN/A
Beta1.69
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone732-537-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.52 billion
Cash Flow$3.37 per share
Book Value$11.27 per share

Profitability

Net Income$137.40 million

Miscellaneous

Employees12,300
Market Cap$7.61 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.


Catalent (NYSE:CTLT) Frequently Asked Questions

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How were Catalent's earnings last quarter?

Catalent Inc (NYSE:CTLT) posted its earnings results on Tuesday, November, 5th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.07. The business earned $664.70 million during the quarter, compared to the consensus estimate of $634.87 million. Catalent had a net margin of 5.77% and a return on equity of 15.30%. The firm's revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.28 EPS. View Catalent's Earnings History.

When is Catalent's next earnings date?

Catalent is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Catalent.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY20 earnings guidance on Tuesday, August, 27th. The company provided EPS guidance of ~$1.89-2.06 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.98. The company issued revenue guidance of $2.78-2.88 billion, compared to the consensus revenue estimate of $2.84 billion.

What price target have analysts set for CTLT?

6 analysts have issued 1 year price targets for Catalent's shares. Their forecasts range from $49.00 to $64.00. On average, they anticipate Catalent's share price to reach $58.67 in the next year. This suggests a possible upside of 12.7% from the stock's current price. View Analyst Price Targets for Catalent.

What is the consensus analysts' recommendation for Catalent?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

Has Catalent been receiving favorable news coverage?

News coverage about CTLT stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Catalent earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Catalent.

Are investors shorting Catalent?

Catalent saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,280,000 shares, an increase of 5.2% from the September 30th total of 4,070,000 shares. Based on an average daily volume of 741,800 shares, the short-interest ratio is currently 5.8 days. Currently, 2.9% of the company's shares are sold short. View Catalent's Current Options Chain.

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Alibaba Group (BABA), Energy Transfer LP Unit (ET), Thermo Fisher Scientific (TMO), CVS Health (CVS), AbbVie (ABBV), Verizon Communications (VZ), Exelixis (EXEL), NVIDIA (NVDA), AT&T (T) and Advanced Micro Devices (AMD).

Who are Catalent's key executives?

Catalent's management team includes the folowing people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 55)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
  • Mr. Alessandro Maselli, Pres & COO (Age 47)

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of of institutional and retail investors. Top institutional investors include GW&K Investment Management LLC (1.37%), Eagle Asset Management Inc. (0.28%), Rhumbline Advisers (0.25%), CWM LLC (0.21%), California Public Employees Retirement System (0.20%) and Ironvine Capital Partners LLC (0.18%). Company insiders that own Catalent stock include Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Peter L Buzy, Steven L Fasman and William Downie. View Institutional Ownership Trends for Catalent.

Which institutional investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Eagle Asset Management Inc., Kornitzer Capital Management Inc. KS, State of Tennessee Treasury Department, Emerald Advisers LLC, Comerica Bank, CWM LLC and Tower Research Capital LLC TRC . Company insiders that have sold Catalent company stock in the last year include Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

Which institutional investors are buying Catalent stock?

CTLT stock was acquired by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, State of New Jersey Common Pension Fund D, Fisher Asset Management LLC, California Public Employees Retirement System, Dorsey Wright & Associates, Mackay Shields LLC, Ironvine Capital Partners LLC and Envestnet Asset Management Inc.. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch and Peter L Buzy. View Insider Buying and Selling for Catalent.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $52.04.

How big of a company is Catalent?

Catalent has a market capitalization of $7.61 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.View Additional Information About Catalent.

What is Catalent's official website?

The official website for Catalent is http://www.catalent.com/.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]


MarketBeat Community Rating for Catalent (NYSE CTLT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  552 (Vote Outperform)
Underperform Votes:  625 (Vote Underperform)
Total Votes:  1,177
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel